« Return to News | Clinical Intelligence

Arena initiates phase I trial of APD811 for hypertension

Friday, October 12, 2012 02:46 PM

Arena Pharmaceuticals, a San Diego-based biopharmaceutical company focused on novel drugs for weight management, cardiovascular disease, inflammation and other disorders, has initiated dosing in a phase I multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

This randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule. Arena previously evaluated single-ascending doses of APD811 in the initial phase I clinical trial.

"Treatment with prostacyclin receptor agonists is considered standard of care for advanced PAH, but approved drugs in this class require intravenous, subcutaneous or inhaled delivery methods," said William R. Shanahan, M.D., senior vice president and CMO, Arena. "APD811 has the potential to improve treatment for this life-threatening disorder by providing patients with an oral, once-daily option targeting the prostacyclin receptor. This drug candidate was discovered internally by our scientists as part of our effort to bring best-in-class treatments to patients."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.